Incubation of serum with 1251-T4: The serum or plasma samples were incubated with radioactive T4 before electrophoresis. For a typical assay, 100 pL of sample was incubated with 10 L of high-specific-activity in serum also can complicate the interpretation of thyroid-function tests (9). Dopending on the RIA procedures used, such antibodies can produce increases or decreases in the apparent concentration of thyroid hormones.
Euthyroid hypothyroxinemia can result from a decreased TBG concentration (7) , the presence of molecular variants of TBG with reduced T4-binding affinity (8), or the euthyroid hypothyroxinemia of illness (the low-T4 state of nonthyroidal illness). For making those differential diagnoses, it would be useful if one could determine the distribution of T4 among the binding proteins and the concentration of protein-bound T4 per unit mass of the respective protein.
In individuals with abnormal T4 concentrations whose results for free T4, thyrotropin, and thyroliberin stimulation tests are within normal limits, the assessment of T4 per unit mass of the binding protein will help in confirming protein-binding abnormality and in distinguishing molecular variants of binding protein from abnormal concentrations of binding protein.
The presence of circulating autoantibodies to thyroid hormones (T4 or triiedothyronine) in serum also can complicate the interpretation of thyroid-function tests (9) . Dopending on the RIA procedures used, such antibodies can produce increases or decreases in the apparent concentration of thyroid hormones.
Methods for assessing protein-binding abnormalities have been described for patients with euthyroid hyperthyroxinemia and euthyroid hypothyroxinemia (10, 11), arid there are methods for detecting the presence of thyroidhormone-binding antibodies (12). Most methods for assessing protein binding are limited by the inability to differentiate molecular variants of the binding proteins. Hence, we describe here a simple radioelectrophoretic method to determine the percentage ofT4 bound to each of the normal thyroid-hormone-binding proteins and to abnormal thyroid hormone-binding immunoglobulins, when present. We calculated the mass ofT4 bound to each protein and determined the mass of each protein to differentiate altered binding affinity from altered protein concentration. We also described how to accurately quantifr the T4 concentration in T4-autoantibody-containing samples.
Materials and Methods

Materials
Highly purified TBG was obtained from American Biosystems, Inc., Stillwater, MN; transthyretin from Calbiochem, La Jolla, CA; human serum albumin, bovine serum albumin, and agarose were from Sigma Chemical Co., St.
Louis, MO; and high-specific-activity radiolabeled thyroxin (I-T4; 4400 kCilmol) was from DuPont, Wilmington, DE.
We prepared radioiodinated TBG, transthyretin, and albumin, using Chioramine T as originally described by Hunter and Greenwood (13). unit with a water cooling system. To each plate we applied 20 mA for 2.5 h. At the end of the electrophoresis, the gels were carefully removed and dried under a 500-W heat lamp for 1 h. The dried gels were sliced into 3-mm segments and the radioactivity of each piece was counted in a gamma counter. Figure 1 shows a plot of radioactivity vs gel slice number.
The radioactivity in the electrophoretogram was also scanned in an automated system (Auto Microbiology System, Inc., San Diego, CA). In some experiments, the gels were also autoradiographed and the peaks were measured with a densitometer.
The radioactive peaks coincided in all the three methods. We identified the specific protein peaks by using pure proteins and staining with Amido Black or by using radioiodinated proteins: TBG, albumin, or transthyretin. To localize the various binding proteins, we routinely ran on each plate nonradiolabeled human serum albumin and serum and calculated the R values for each binding protein. The arrows Indicate the mobility of various purified protein markers, as determined by electrophoresis of radioiodinated binding proteins activity, determined routinely in each run, was 75%. Quantification of T4-binding proteins: Albumin and transthyretin were determined with an automated protein analyzer ("Array"; Beckman Instruments, Brea, CA). This is a rate-nephelometric assay in which specific antibodies are used for the binding proteins (14). The intra-assay coefficients of variation (CV) for albumin and transthyretin were 1% and 1.2%; the interassay CVs were 2.0% and 2.6%, respectively. We estimated TBG content by direct radioimmunoassay with use of '251-labeledTBG and antibodies to TBG (15) . The assay is highly specific; there is <0.01% cross-reactivity with albumin and transthyretin.
The intraand interassay
CVs were 5% and 8%, respectively.
Quantification of T4:
To measure total T4 in the serum samples, we used a radioimmunoassay procedure (16) involving '25I-T4 and anti-T4 antibodies in the presence of a T4-binding inhibitor (anilinonaphthalenesulfonic acid). For the bound/free separation, we used a 250 g/L solution of polyethylene glycol (125 g/L final concentration). The assay is sensitive and specific for T4 (16). Intra-and interassay CVs were 4% and 7%, respectively. However, this assay could not be used for samples containing anti-T4. Use of neither a second-antibody separation step nor a high concentration of anilinonaphthalenesulfonic acid allowed accurate determination of total T4 in the presence of T4-binding autoantibodies.
Thus, T4 bound to anti-T4 was released by using HC1 (0.1 mol/L), and the T4 antibody was precipitated with polyethylene glycol, as previously doscribed for the assay of insulin in sera containing insulin antibodies (17) . The mixture was centrifuged, Clinical samples: Serum or plasma samples were obmined from normal volunteers at Nichols Institute.
Hy-
pothyroid, hyperthyroid, TBG-deficient, TBG-excess, and T4-antibody-containing samples were taken from specimens sent to the Reference Laboratory. corresponded to the standard protein peaks as run in the same gel and stained with Amido Black. An additional radioactive peak could be demonstrated in the gamma globulin region in samples containing antibodies to T4 ( Figure 1B) . Total T4 was quantified by direct radioimmunoassay in all samples except those with autoantibody to T4. In the latter, the samples were treated with HC1to release 'F4, and antibody to T4 was removed by precipitation with polyethylene glycol. After antibody removal the T4 concentration was determined by radioimmunoassay. This procedure resuited in accurate assessment of T4 concentration; values for T4 in the treated samples, when diluted, paralleled those on standard curve for T4. Low concentrations of all three forms of protein-bound T4 were seen in samples from hypothyroid patients, in samples containing T4 autoantibody, and in samples from the euthyroid hypothyroxinemia of illness. Table 1 lists the ranges found for TBG, transthyretin, and albumin in the controls. Figure 3 shows the concentrations in the various clinical disorders we studied. TBG concentrations were abnormal only in samples from patients with TBG deficiency or excess conditions. Albumin and transthyretin were low in some patients with the euthyroid hypothyroxinemia of nonthyroidal illness. It has been shown that FDH and TBG variant proteins have an altered affinity for T4 (3, 20) . To determine whether the present methods can distinguish abnormalities of protein Table 1 a.
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Fig. 3. Concentrations of TBG, prealbumin, and albumin in various clinicalconditions
Shaded area: the normalreferenceinterval for each protein
Discussion
The use of radiolabeled T4 and serum protein electrophoresis to assess the distribution of T4 in various binding proteins is well documented (10, 11, 21, 22). Our electrophoresis procedure is specific and reproducible, TBG, transthyretin, and albumin being well separated ( Figure IA ). T4-binding antibodies can also be identified easily with this procedure ( Figure 1B) The distribution ofT4 among binding proteins can be determined in various clinical conditions (Figure 2) . It is possible to quantify concentrations of binding protein and diagnose patients with abnormally high or low concentrations of T4-binding proteins (Figure 3) by using sensitive inununoassays. Several methods have been described to characterize molecular variants of albumin, including Scatchard plot (4, 20) and saturation with nonradioactive T4 (11). Preparation of Scatchard plots is tedious, and they have been applied to only one binding protein at a time. Saturation with nonradioactive T4 with electrophoresis produces variable results, because constant amounts of T4 are used even though the concentration of binding proteins is variable. The present procedure is simple and can be used to assess all three of the T4-binding proteins. When the concentration ofT4 bound to each protein is expressed per unit mass of protein, only proteins with altered affinities show abnormal distributions (Figure 4) . This method can be used for the diagnosis of all the described T4-binding protein variants, including the TBG variant, the dysalbuminemic variant, and the transthyretin variant. When the T4 distribution is abnormal and involves all of In clinical practice, diagnosis and follow-up of patients with thyroid disorders is commonly accomplished by applying T4 A procedures, and T4-binding abnormalities can cause factitious results for P4. Recent developments in TSH assay sensitivity minimize diagnostic errors and help in the management of thyroid disorders. However, when results for thyroxin or the free-thyroxin index are not consistent with the clinical situation or with the TSH concentrations, it is important to consider the possibility of T4-binding-protein abnormalities.
The method described here allows, for the first, time, rapid and reliable determination of the various causes of euthyroid hyperthyroxinemia and euthyroid hypothyroxinemia.
In addition, it may be helpful and important to distinguish genetic molecular variants of the T4-binding proteins from disease-related abnormalities in protein concentrations.
In the latter, the discovery of abnormal thyroid-hormone-binding protein concentrations may be the first evidence of previously unrecognized organic disease. Applying the presently described method, one can now characterize the type of T4-binding abnormality in individual patients encountered in clinical practice.
